<i>MicroRNA-34a</i>/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
Ryo Yokomizo(Jikei University School of Medicine), Aikou Okamoto(Jikei University School of Medicine)
Cited by 10
Related Papers
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
|Gynecologic Oncology|2022|15